Skip to main content
Loading

Precision targeting without broad immunosuppresion for autoimmune diseases

20 Feb 2025
Immune Regulation
  • Current Challenges: What are the primary limitations of existing broad immunosuppressive therapies in terms of efficacy, safety, and patient quality of life?

  • Innovative Strategies: What are the most promising approaches for achieving precision targeting in autoimmune disease treatment.

  • Translational Hurdles.

Industry Expert
Doug Ethell, Founder and Chief Executive Officer - Leucadia Therapeutics